Dr. Anton Franken is a Consultant Internal Medicine and Clinical Expert in Drug (Biosimilar) Development, especially in Phase I – II Clinical Trials.
Dr. Franken is an expert in Biosimilars development and a former member of the Dutch Medicines Evaluation Board (CBG-MEB ) and a former Board member of Biosimilars Nederland (IBN).
Dr. Michał Nowicki is a medical professional with degrees in Medicine and Pharmacy from the Poznan University of Medical Sciences. As a Medical Officer and Consultant at Biokinetica Early Phase Institute in Berlin, he oversees active clinical trials, prepares reports, engages with sponsors, and qualifies volunteers for First-in-Human trials. His expertise also includes Biosimilars and their development.
Previously, Dr. Nowicki worked as a Medical Resident at the Cardinal Wyszynski Institute of Cardiology in Warsaw, where he focused on innovative therapy methods in the Intensive Cardiac Care Unit. He also served as a lecturer at the Poznan University of Medical Sciences, focusing on Telemedicine.
Clinical Research Services Europe at ICON, 36 years of Clinical Development & General Management experience, covering all phases of drug development I-IV, including most Therapeutic Areas, including both major Pharma (Abbott laboratories & Schering Plough) as well as major Biotech (Amgen) and CRO experience (Kendle, INC).
Medical background with Medical Doctor license from Erasmus University Rotterdam, 1985, followed by 4 years of clinical experience in direct patient care in internal medicine and cardiology.
>20 years in early-phase clinical research and management of more than 100 studies, responsible for operational excellence, client relations, business development, and strategic growth. Founding President of the POLFEMED Association.
